CNPV: A gamechanger for the pharma industry or simply more chaos?

The FDA’s Commissioner’s National Priority Voucher (CNPV) pilot program was announced in June 2025 to reduce review times for drug and biological products down to 1-2 months compared with 6+ months for conventional drug and biological product applications by implementing a “tumor board” style review process. The program was envisioned to expedite review process of drug and biologic products to address key US national health priorities such as urgent and emergent threats of significant population impact, transformative treatments with novel mechanism of action that may change disease management, large unmet medical need, and to onshore manufacturing for supply chain resilience and to promote affordability.

Unlike Priority Review Vouchers (PRVs), CNPVs are non-transferable and permit enhanced pre-submission requests with the FDA, facilitating an expedited rolling review process conceptually similar to elements of the RTOR program. Companies are encouraged to apply through a simplified form, with justification limited to 350 words – notably less complex than standard application processes associated with other expedited pathways. Vouchers are awarded on a rolling basis, although no formal limits on the number of vouchers in circulation have been publicly defined. Notably, the application process does not currently specify minimum supporting data requirements, raising the possibility that CNPVs could be granted to assets in early-phase development and potentially used in support of accelerated approval strategies, rather than more robust Phase 3 data packages intended for full approvals.

As an early-stage pilot, several elements of the program remain under development. At present, there are limited publicly articulated constraints around the volume of applications or formalized selection criteria, and the FDA has also issued a number of CNPVs prospectively without requiring a formal application. While this flexibility may support responsiveness and efficiency during the pilot phase, it has also introduced some uncertainty across the industry regarding how assets are prioritized and how demand for the program will be managed over time. Of note, initial approvals within the CNPV program were primarily for previously approved products, as seen with Augmentin XR, where elements of the evidentiary package had already been assessed by the FDA. As the pilot has progressed, however, assets without prior approvals are beginning to be granted approvals. As the program continues and more novel, previously unapproved assets are assessed, it remains to be seen how consistently these accelerated timelines can be maintained.

A recent public hearing for the CNPV program highlighted the fact that perceptions of the CNPV program remain divided. Industry stakeholders were generally supportive of the program, citing accelerated reviews without compromising scientific rigor. Physicians and public health experts expressed concerns over transparency, governance and potential political influence the program could precipitate and called for stronger procedural safeguards. Patient advocacy groups noted support for the program, indicating its potential use to expedite the review process to accelerate therapies for serious, progressive and rare diseases. However, feedback largely focused on improving transparency, predictability, and governance rather than eliminating the program, suggesting broad support for FDA’s efforts to accelerate review of high-priority therapies while maintaining scientific rigor.

In this article, we examine the short-term real-world impact of the program, highlighting operational uncertainties, regulatory bottlenecks, and inconsistencies in corporate communication, before extending to forward-looking considerations around regulatory policy, launch strategy, and competitive intelligence.

Table 1: Select CNPV-awarded assets

Asset	CNPV Issued	FDA Decision	Time from CNPV issuance to Decision (Days)	Comments
Hernexeos (zongertinib; HER2-TKI)	Nov 6, 2025	Approved (Feb 26, 2026)	112 days	HER2m NSCLC
Augmentin XR (amoxicillin/clavulanate; β-lactam/β-lactamase inhibitor)	Oct 16, 2025	Approved (Dec 10, 2025)	55 days	Domestic antibiotic manufacturing
Foundayo (orforglipron; oral GLP-1 RA)	Nov 6, 2025	Approved (Apr 1, 2026)	146 days	First NME approved via CNPV
Wegovy (semaglutide; GLP-1 RA)	Nov 6, 2025	Approved (Mar 20, 2026)	134 days	Higher-dose semaglutide
Otarmeni (DB-OTO; AAV1-OTOF gene therapy)	Oct 16, 2025	Approved (Apr 23, 2026)	134 days	First gene therapy approved via CNPV
Bitopertin (glyT1 inhibitor)	Oct 16, 2025	CRL (Feb 13, 2026)	120 days	Porphyria
Tecvayli (teclistamab; BCMAxCD3 BiTe) + Darzalex Faspro (SC daratumumab; anti-CD38 mAb)	Dec 15, 2025	Approved (Mar 5, 2026)	80 days	MM combo
Bizengri (zenocutuzumab; HER2xNRG1 bsAb)	May 5, 2026	Approved (May 8, 2026)	3 days	NRG1+ cholangiocarcinoma
Pergoveris (follitropin alfa + lutropin alfa)	Oct 16, 2025	N/A	N/A	Fertility (U.S. Food and Drug Administration)
Tzield (teplizumab)	Oct 16, 2025	N/A	N/A	Type 1 diabetes (U.S. Food and Drug Administration)
Cytisinicline	Oct 16, 2025	N/A	N/A	Nicotine vaping addiction (U.S. Food and Drug Administration)
Oxervate (cenegermin)	Oct 16, 2025	N/A	N/A	Blindness/corneal disease (U.S. Food and Drug Administration)
RMC-6236	Oct 16, 2025	N/A	N/A	Pancreatic cancer (U.S. Food and Drug Administration)
Ketamine (domestic manufacturing)	Oct 16, 2025	N/A	N/A	US manufacturing priority (U.S. Food and Drug Administration)
Sirturo (bedaquiline)	Nov 6, 2025	N/A	N/A	Pediatric drug-resistant TB (U.S. Food and Drug Administration)
Jemperli (dostarlimab)	Nov 6, 2025	N/A	N/A	Rectal cancer (U.S. Food and Drug Administration)
Casgevy (exagamglogene autotemcel)	Nov 6, 2025	N/A	N/A	Sickle cell disease (U.S. Food and Drug Administration)

Table 2: Average time from a CNPV decision to approval

Indication Group	Approved Assets Included	Average Time from CNPV issuance to Decision (Days)	Average Time (Months)
Overall	7 approved assets	94.9 days	3.1 months
Oncology / Hematology	Hernexeos, Tecvayli + Darzalex Faspro, Bizengri	65.0 days	2.1 months
Obesity / Metabolic	Foundayo, Wegovy	140.0 days	4.6 months
Anti-infective / Antibiotics Supply	Augmentin XR	55.0 days	1.8 months
Rare Disease / Genetic / Sensory Disorders	Otarmeni	134.0 days	4.4 months

Short-term reality: Fast approvals, murky details

The FDA has consistently reported review timelines for CNPV-based approvals as falling within the 1-2-month target range. However, while several companies have publicly stated intent to file using CNPV, none of the currently approved assets via this pathway had previously disclosed their filing dates, possibly reflecting the absence of standardized disclosure requirements. Bizengri represents the clearest example, with only three days between CNPV issuance and stated approval decision. Consequently, this makes validation of the FDA’s stated review timelines challenging.

It is additionally notable that of the current seven approvals via CNPV pathway, only Eli Lilly’s Foundayo and Regeneron’s Otarmeni represent novel approvals by the FDA. The conventional supplementary approval pathway is associated with shorter review times, and as such, the pilot program’s apparent bias towards previously approved assets could make it possible for the shorter CNPV review period to be achieved. This may represent a cautious approach by the FDA to stress-test this new approval pathway with applications of a lower assessment burden ahead of a wider rollout. However, this could equally be interpreted as regulatory conservatism regarding the feasibility of consistently achieving ambitious review targets for more complex or novel candidates, despite the agency’s emphasis on meeting review timelines performance in public communications.

It is reasonable to question whether future potential approvals could also meet review timelines, particularly as the program expands with more novel assets assessed and the burden on the regulators increases. The FDA has not yet provided a roadmap on the future of the program, nor guidance regarding the number of CNPVs it expects to issue annually, or whether the current two-year expiry limit will continue to apply.

The early bias toward previously approved assets may have the unintended consequence of benefiting “Big Pharma”, who could be considered better placed to deliver the stated aims of the program, including addressing major unmet needs. To date, this distribution appears to reflect this dynamic, with more than 80% of CNPV approvals and over 50% of CNPVs issued going to Big Pharma or connected assets. While the simplified application process ostensibly may aid smaller biotech companies due to lower associated application costs, the lack of transparency regarding selection rationale raises the question of how companies should benchmark asset readiness, manufacturing capabilities and optimal regulatory pathway selection.

The lack of publicly announced filings also raises the question of whether the CNPV may engender a change in the status quo for conventional regulatory disclosures. While companies typically announce FDA submissions as a matter of course, it is not a regulatory requirement. Companies may observe the competitive benefits of “surprise” approval announcements, with competitors spending resources on closely monitoring alternative avenues for indications of imminent approval, such as launch preparations, manufacturing activity or adjacent filings; there is a plausible risk that companies may revert to the strategy of withholding filing announcements across all regulatory applications. Conversely, public disclosure of regulatory filings can reassure investors by increasing transparency around development timelines and key milestones. Such announcements also help support more informed market expectations ahead of potential approval decisions. However, if filing disclosure become less common under the influence of the CNVP pathway, it must be considered that this shift may further benefit companies with greater capacity to invest in continuous competitive intelligence and monitoring activities. Overall, uncertainty is the name of the game as the CNPV program currently stands, and the pharmaceutical industry is closely observing the state of play and where this will move.

Looking to the future: Scalable model or stretch too far?

As the CNPV pilot program continues to evolve, several questions remain regarding its long-term role within the broader FDA regulatory framework. While the program has demonstrated measurable success, including eight regulatory decisions each made in less than six months, it remains unclear whether the current model is sustainable, particularly in regard to regulatory transparency and applicability to novel MOAs. The program’s close alignment with US policies relating to public health preparedness and domestic manufacturing resilience, seems to suggest that the CNPV is here to stay. However, continued refinement of the pathway, potentially addressing the opacity surrounding the eligibility criteria and operational guidance, as well as more standardized disclosure practices is likely required to ensure the programs survival. Additionally, recent changes within the FDA, including the departure of Commissioner Marty Makary, may introduce additional uncertainty around the program’s future and leave open the possibility of a major redesign or suspension.

The question of compressed review timeline consistency may become particularly relevant in oncology and rare disease settings, where approvals are increasingly supported by surrogate endpoints (e.g. MRD negative CR in AML), biomarker defined populations (e.g. KRAS G12X in NSCLC) and single-arm studies (e.g. for rare diseases or areas of high unmet need). In such cases, balancing expedited review with evidentiary confidence may prove more challenging, particularly if post-marketing commitments become increasingly central to approval decisions. Notably, accelerated regulatory timelines do not necessarily equate to accelerated uptake post-launch. Payers, prescribers and patients alike may discriminate between therapies approved through a rapid but controversial and standard but conventional review program. Additionally, the FDA itself may impose post-market requirements; despite rapid CNPV approval, Lilly’s Foundayo (orforglipron; GLP-1) was subject to multiple FDA-mandated postmarketing studies and five years of enhanced pharmacovigilance focused on liver and cardiovascular safety. As such, companies leveraging the CNPV pathway may need to place a greater emphasis on post-launch evidence generation and educating target groups to build confidence across patient and market networks.

As mentioned above, the CNPV program appears to favor ‘Big Pharma’, with potential implications for the launch strategy and strategic partnering. Larger companies, typically more capable of rapidly scaling manufacturing, management accelerated information request and coordinating compressed launch timelines are likely to benefit from the model, reflected in the proportion of the industry who both hold and have used vouchers. Meanwhile, smaller innovative biotechs lacking in established regulator infrastructure and domestic US manufacturing capacity may either fail to qualify for the voucher or be structurally incapable of capitalizing on the acquired advantage. This set of circumstances could establish a dynamic of smaller companies increasingly seeking strategic partnerships earlier in development to ensure sufficient operational readiness for accelerated commercialization.

Uncertainty on the program’s future extends beyond the borders of the US. While the EMA and CHMP are unlikely to directly replicate the CNPV scheme in the near-term, the pathway could contribute to increasing divergence between US and EU approval timelines and therefore regulatory strategies. Given the evidentiary bar for FDA accelerated approval is already lower compared to EU equivalents, such as utilizing earlier phase, single-arm studies, widespread use of the CNPV in the US over time could exacerbate this discrepancy. Companies face an additional strategic risk, as an FDA approval no longer signals a likely success, potentially forcing companies to consolidate pipelines or navigate conflicting regulatory advice which may delay global clinical trial programs.

Overall, the CNPV program represents a potentially significant evolution in FDA regulatory strategy, reflecting a broader willingness to reconsider conventional review paradigms for selected priority therapies. However, many aspects of the pathway remain operationally and strategically immature. As the pilot develops, the degree to which the FDA introduces additional transparency, standardization and predictability may ultimately determine whether the CNPV evolves into a fairer, more sustainable and scalable regulatory pathway or remains a less predictable but still strategically valuable quid pro quo.

Competitive Intelligence implications: More guesswork, more groundwork

Again, while FDA guidance for CNPV reviews suggests a 1–2-month review period, decisions granted thus far under the program to date indicate that forecasting approval timelines may be more complex than a straightforward timing exercise. Although the CNPV pathway was established to accelerate review of therapies considered to be of national importance, limited sponsor disclosure regarding anticipated decision timing and variable review durations observed across case studies complicate assessment of whether reviews across indications and asset classes can consistently align with the FDA’s stated benchmark. Across assets granted CNPV thus far, average duration from CNPV filing for approval to an approval decision has been ~3.1 months, exceeding the 1–2-month guidance. Furthermore, early case studies suggest potential indication-driven variability in review duration, although it remains unclear whether this reflects a durable pattern or early-stage variability that may normalize as the FDA gains experience with the program and streamlines review processes.

Lack of clarity surrounding both review duration and indication attribution, particularly where CNPVs may not be explicitly linked to a specific indication (e.g. zongertinib and sacituzumab tirumotecan), reinforces the importance of robust competitive intelligence monitoring following CNPV assignment. Alongside effective secondary monitoring, primary intelligence from sponsor-adjacent, regulatory, and clinical sources may become increasingly important to track evolving timelines and competitor activity.

This uncertainty accompanying CNPV awards could require substantially greater monitoring resources than those allocated to traditional regulatory pathways. As adoption expands across indications and asset classes, organizations may need to implement more intensive and sustained monitoring strategies to evaluate competitor timelines and broader regulatory dynamics. This increased effort presents a particular challenge in the context of a constrained biotech market and tightening operating budgets, where expanding CI investment may not be readily feasible. As such, organizations may increasingly need to prioritize targeted and risk-based CI approaches, concentrating resources on high-priority competitors and assets most likely to influence competitive positioning.

Concurrently, AI-enabled monitoring tools could play an increasingly important role in supporting CNPV-related intelligence efforts. Automation of secondary monitoring, including regulatory domain surveillance, company disclosures, scientific conference tracking, and signal detection across disparate information sources, may help offset growing monitoring burdens without requiring proportional increases in CI headcount or spend. However, while AI may improve efficiency and broaden monitoring coverage, it is unlikely to fully replace the need for human analytical judgment and primary intelligence efforts. Given the limited transparency and evolving nature of the CNPV pathway, sponsor-adjacent, regulatory-process, and clinical sources will likely remain critical to contextualize signals and provide clarity on approval timing and competitive intent.

About the authors

---

Filed Under: Regulatory affairs
Tagged With: accelerated approval, Big Pharma, biotechnology, CNPV, Commissioner's National Priority Voucher, competitive intelligence, drug development, drug launch strategy, drug review process, FDA, pharmaceutical industry, priority review, regulatory affairs
 

---